HRP20191095T1 - Humanizirano anti kallikrein-2 antitijelo - Google Patents
Humanizirano anti kallikrein-2 antitijelo Download PDFInfo
- Publication number
- HRP20191095T1 HRP20191095T1 HRP20191095TT HRP20191095T HRP20191095T1 HR P20191095 T1 HRP20191095 T1 HR P20191095T1 HR P20191095T T HRP20191095T T HR P20191095TT HR P20191095 T HRP20191095 T HR P20191095T HR P20191095 T1 HRP20191095 T1 HR P20191095T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody polypeptide
- polypeptide according
- seq
- amino acid
- constant region
- Prior art date
Links
- 101710176220 Kallikrein-2 Proteins 0.000 title claims 2
- 102000057032 Tissue Kallikreins Human genes 0.000 title claims 2
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical class OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims 2
- 229960000958 deferoxamine Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- FHQWIXXRHHMBQL-UHFFFAOYSA-N 2-[1,3,10-tris(carboxymethyl)-1,3,6,10-tetrazacyclododec-6-yl]acetic acid Chemical class OC(=O)CN1CCCN(CC(O)=O)CCN(CC(O)=O)CN(CC(O)=O)CC1 FHQWIXXRHHMBQL-UHFFFAOYSA-N 0.000 claims 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical class OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Polipeptid antitijela sa specifičnošću vezanja za humani kallikrein-2 (hK2), pri čemu polipeptid antitijela obuhvaća
(a) varijabilni predio teškog lanca koji obuhvaća ili se sastoji od sekvence aminokiseline SEQ ID NO:8; i
(b) varijabilni predio lakog lanca koji obuhvaća ili se sastoji od sekvenci aminokiselina SEQ ID NO:9.
2. Polipeptid antitijela prema Zahtjevu 1, koji sadrži ili se sastoji od intaktnog antitijela ili fragmenta za vezanje antigena koji je izabran iz grupe koja se sastoji od Fv fragmenata i fragmenata sličnih Fab.
3. Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, koji dalje obuhvaća konstantni predio teškog lanca, ili njegov dio, pri čemu je konstantni predio teškog lanca podtip imunoglobulina koji je izabran iz grupe koja se sastoji iz IgG1, IgG2, IgG3 i IgG4.
4. Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, koji dalje obuhvaća konstantni predio lakog lanca, ili njegov dio, pri čemu je konstantni predio lakog lanca kappa ili lambda laki lanac.
5. Polipeptid antitijela prema Zahtjevu 3 ili 4, koji obuhvaća konstantni predio teškog lanca koji sadrži ili se sastoji od sekvence aminokiselina SEQ ID NO: 10 i/ili konstantni predio lakog lanca koji sadrži ili se sastoji od sekvence aminokiselina SEQ ID NO: 11.
6. Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, koji obuhvaća teški lanac koji sadrži ili se sastoji od sekvence aminokiselina SEQ ID NO: 12 i/ili laki lanac koji sadrži ili se sastoji od sekvence aminokiselina SEQ ID NO: 13.
7. Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, pri čemu je polipeptid antitijela povezan, direktno ili indirektno, sa terapijskim dijelom.
8. Polipeptid antitijela prema bilo kojim prethodnim zahtjevima, pri čemu polipeptid antitijela dalje obuhvaća detektabilan dio.
9. Polipeptid antitijela prema Zahtjevu 7 ili 8, pri čemu je terapijski dio i/ili detektabilan dio indirektno spojen sa polipeptidom antitijela, preko dijela za povezivanje.
10. Polipeptid antitijela prema Zahtjevu 9, gdje je dio za povezivanje kelat koji je izabran iz grupe koja se sastoji od derivata 1,4,7,10-tetraaza-ciklododekan-1,4,7,10,tetraoctene kiseline (DOTA), deferoksamina (DFO), derivata dietilentriaminpentaoctene kiseline (DTPA), derivata S-2-(4-izotiocijanatobenzil)-1,4,7-triazaciklononan-1,4,7-trioctene kiseline (NOTA) i derivata 1,4,8,11-tetraazaciklododekan-1,4,8,11-tetraoctene kiseline (TETA).
11. Izolirana molekula nukleinske kiseline koja kodira polipeptid antitijela prema bilo kojem od prethodnih zahtjeva.
12. Molekula nukleinske kiseline prema Zahtjevu 11, koja obuhvaća nukleotidnu sekvencu SEQ ID NO: 14 i/ili SEQ ID NO: 15.
13. Farmaceutski sastav koji obuhvaća polipeptid antitijela prema bilo kojim Zahtjevima 1 do 10 i farmaceutski prihvatljiva pomoćna tvar, razrjeđivač ili nosač.
14. Polipeptid antitijela prema bilo kojim Zahtjevima 1 do 10 za upotrebu u medicini.
15. Polipeptid antitijela prema bilo kojim Zahtjevima 1 do 10 za upotrebu u liječenju i/ili dijagnozi raka prostate.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1320408.6A GB2520353A (en) | 2013-11-19 | 2013-11-19 | Antibody polypeptides and uses thereof |
| GB201401973A GB201401973D0 (en) | 2014-02-05 | 2014-02-05 | Antibody polypeptides and uses thereof |
| EP14814696.2A EP3071595B1 (en) | 2013-11-19 | 2014-11-19 | Humanised anti kallikrein-2 antibody |
| PCT/GB2014/053420 WO2015075445A1 (en) | 2013-11-19 | 2014-11-19 | Humanised anti kallikrein-2 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191095T1 true HRP20191095T1 (hr) | 2019-09-20 |
Family
ID=52114029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191095TT HRP20191095T1 (hr) | 2013-11-19 | 2019-06-17 | Humanizirano anti kallikrein-2 antitijelo |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10100125B2 (hr) |
| EP (2) | EP3071595B1 (hr) |
| JP (3) | JP6599859B2 (hr) |
| KR (3) | KR102442738B1 (hr) |
| CN (1) | CN105980404B (hr) |
| AU (3) | AU2014351611B2 (hr) |
| BR (1) | BR112016011025B1 (hr) |
| CA (1) | CA2930493A1 (hr) |
| CY (1) | CY1121900T1 (hr) |
| DK (1) | DK3071595T3 (hr) |
| ES (1) | ES2728515T3 (hr) |
| HR (1) | HRP20191095T1 (hr) |
| HU (1) | HUE043875T2 (hr) |
| IL (4) | IL297678B1 (hr) |
| LT (1) | LT3071595T (hr) |
| MX (2) | MX2016006561A (hr) |
| PL (1) | PL3071595T3 (hr) |
| PT (1) | PT3071595T (hr) |
| RS (1) | RS58831B1 (hr) |
| RU (1) | RU2687163C1 (hr) |
| SI (1) | SI3071595T1 (hr) |
| WO (1) | WO2015075445A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3071595T3 (pl) * | 2013-11-19 | 2019-09-30 | Fredax Ab | Humanizowane przeciwciało przeciw kalikreinie-2 |
| SG10201808585TA (en) | 2014-03-28 | 2018-11-29 | Opko Diagnostics Llc | Compositions and methods related to diagnosis of prostate cancer |
| DK3253800T3 (da) | 2015-03-27 | 2021-05-31 | Opko Diagnostics Llc | Prostata antigen standarder og bruge deraf |
| WO2017087826A1 (en) * | 2015-11-18 | 2017-05-26 | Memorial Sloan Kettering Cancer Center | Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods |
| JP7105235B2 (ja) | 2016-12-01 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| KR102351556B1 (ko) * | 2017-03-30 | 2022-01-14 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법 |
| US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| JP2022532157A (ja) | 2019-05-10 | 2022-07-13 | ヤンセン バイオテツク，インコーポレーテツド | 大員環キレータ及びその使用方法 |
| CN114174346A (zh) * | 2019-07-26 | 2022-03-11 | 詹森生物科技公司 | 抗hk2嵌合抗原受体(car) |
| JP2022541332A (ja) * | 2019-07-26 | 2022-09-22 | ヤンセン バイオテツク，インコーポレーテツド | カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用 |
| MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
| CA3189293A1 (en) * | 2020-07-17 | 2022-01-20 | Janssen Biotech, Inc. | Anti-idiotypic antibodies against anti-klk2 antibodies |
| TW202233244A (zh) * | 2020-11-10 | 2022-09-01 | 美商健生生物科技公司 | 巨環化合物及其使用方法 |
| CN112608365B (zh) * | 2020-12-22 | 2021-07-30 | 吉林省特医食品生物科技有限公司 | 一种减轻体重的发酵型小分子肽及其制备方法和应用 |
| CN114790245A (zh) * | 2021-01-25 | 2022-07-26 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| MX2023008803A (es) | 2021-01-27 | 2023-08-04 | Janssen Biotech Inc | Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos. |
| AU2022282866A1 (en) | 2021-05-27 | 2024-01-18 | Janssen Biotech, Inc. | Compositions and methods for the treatment of prostate cancer |
| CA3236851A1 (en) | 2021-11-09 | 2023-05-19 | Janssen Biotech, Inc. | Macrocyclic compounds and diagnostic uses thereof |
| WO2023084396A1 (en) | 2021-11-09 | 2023-05-19 | Janssen Biotech, Inc. | Macrocyclic compounds and methods of making the same |
| WO2023144723A1 (en) | 2022-01-26 | 2023-08-03 | Janssen Biotech, Inc. | Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| US6379669B1 (en) | 1995-08-04 | 2002-04-30 | Akhouri A. Sinha | Targeting of organs by immunoconjugates |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| EP0941368A2 (en) | 1996-11-14 | 1999-09-15 | Mayo Foundation For Medical Education And Research | Method for detection of metastatic prostate cancer |
| US7053042B1 (en) | 1999-07-29 | 2006-05-30 | Samuel Denmeade | Activation of peptide prodrugs by hK2 |
| WO2001012218A1 (en) | 1999-08-16 | 2001-02-22 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
| FI20002127A0 (fi) | 2000-09-27 | 2000-09-27 | Artic Partners Oy Ab | Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi |
| EP2277542B1 (en) | 2001-06-01 | 2014-04-16 | Cornell Research Foundation Inc. | Modified antibodies to prostrate-specific membrane antigen and uses thereof |
| AU2002362447A1 (en) | 2001-10-03 | 2003-04-14 | University Of Rochester | Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2 |
| CA2492671C (en) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US7867475B2 (en) | 2003-01-31 | 2011-01-11 | Universidad Autonoma De Madrid | Immune regulation based on the depletion of CD69+ cells |
| WO2005094882A1 (en) * | 2004-03-03 | 2005-10-13 | Millennium Pharmaceuticals, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| US8663600B2 (en) | 2005-02-17 | 2014-03-04 | Diaprost Ab | Diagnosis of prostate cancer |
| EP1851251A2 (en) * | 2005-02-18 | 2007-11-07 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| MX2009005776A (es) | 2006-12-01 | 2009-06-10 | Medarex Inc | Anticuerpos humanos que se enlazan al cd 22 y sus usos. |
| JP5523108B2 (ja) * | 2006-12-22 | 2014-06-18 | ファディア・アクチボラグ | 新規アレルゲンとしての前立腺カリクレイン |
| WO2010045340A1 (en) * | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Methods of humanizing and affinity-maturing antibodies |
| KR102362358B1 (ko) * | 2011-10-28 | 2022-02-15 | 프레닥스 에이비 | 치료제 및 이의 용도 |
| PL3071595T3 (pl) * | 2013-11-19 | 2019-09-30 | Fredax Ab | Humanizowane przeciwciało przeciw kalikreinie-2 |
-
2014
- 2014-11-19 PL PL14814696T patent/PL3071595T3/pl unknown
- 2014-11-19 KR KR1020167016169A patent/KR102442738B1/ko active IP Right Grant
- 2014-11-19 KR KR1020237029468A patent/KR20230132599A/ko not_active Application Discontinuation
- 2014-11-19 HU HUE14814696A patent/HUE043875T2/hu unknown
- 2014-11-19 AU AU2014351611A patent/AU2014351611B2/en active Active
- 2014-11-19 WO PCT/GB2014/053420 patent/WO2015075445A1/en active Application Filing
- 2014-11-19 EP EP14814696.2A patent/EP3071595B1/en active Active
- 2014-11-19 SI SI201431143T patent/SI3071595T1/sl unknown
- 2014-11-19 BR BR112016011025-0A patent/BR112016011025B1/pt active IP Right Grant
- 2014-11-19 RU RU2016124229A patent/RU2687163C1/ru active
- 2014-11-19 PT PT14814696T patent/PT3071595T/pt unknown
- 2014-11-19 JP JP2016532031A patent/JP6599859B2/ja active Active
- 2014-11-19 IL IL297678A patent/IL297678B1/en unknown
- 2014-11-19 KR KR1020227003223A patent/KR102574537B1/ko active IP Right Grant
- 2014-11-19 CA CA2930493A patent/CA2930493A1/en active Pending
- 2014-11-19 EP EP19161698.6A patent/EP3553088A1/en active Pending
- 2014-11-19 LT LTEP14814696.2T patent/LT3071595T/lt unknown
- 2014-11-19 IL IL311788A patent/IL311788A/en unknown
- 2014-11-19 ES ES14814696T patent/ES2728515T3/es active Active
- 2014-11-19 RS RS20190729A patent/RS58831B1/sr unknown
- 2014-11-19 MX MX2016006561A patent/MX2016006561A/es unknown
- 2014-11-19 CN CN201480072422.8A patent/CN105980404B/zh active Active
- 2014-11-19 US US15/036,170 patent/US10100125B2/en active Active
- 2014-11-19 DK DK14814696.2T patent/DK3071595T3/da active
-
2016
- 2016-05-11 IL IL245617A patent/IL245617B/en active IP Right Grant
- 2016-05-19 MX MX2021007006A patent/MX2021007006A/es unknown
-
2018
- 2018-08-30 US US16/117,522 patent/US11230609B2/en active Active
-
2019
- 2019-06-17 HR HRP20191095TT patent/HRP20191095T1/hr unknown
- 2019-06-20 CY CY20191100645T patent/CY1121900T1/el unknown
- 2019-10-02 JP JP2019181801A patent/JP7051777B2/ja active Active
-
2020
- 2020-07-20 AU AU2020207775A patent/AU2020207775B2/en active Active
- 2020-11-04 IL IL278493A patent/IL278493B2/en unknown
-
2021
- 2021-09-16 US US17/476,683 patent/US20220064333A1/en active Pending
-
2022
- 2022-01-13 JP JP2022003634A patent/JP2022062048A/ja active Pending
-
2023
- 2023-08-30 AU AU2023222879A patent/AU2023222879A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191095T1 (hr) | Humanizirano anti kallikrein-2 antitijelo | |
| JP7487250B2 (ja) | 標的分子に対する抗原結合コンストラクト | |
| HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
| ES2919879T3 (es) | Sustratos escindibles con metaloproteasa de matriz y con serina proteasa y procedimientos de uso de los mismos | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| ES2784131T3 (es) | Polipéptidos de unión beta del receptor PDGF | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| ES2773504T3 (es) | Nuevo polipéptido que tiene afinidad por PD-L1 | |
| RU2015151505A (ru) | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) | |
| BRPI0412245A (pt) | anticorpos de rg1 e usos destes | |
| HRP20201064T1 (hr) | Postupci liječenja tauopatije | |
| JP2019527194A5 (hr) | ||
| RU2010127292A (ru) | Антитело против nr10 и его применение | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| CN105813654A (zh) | Tem8抗体及其用途 | |
| UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| RU2010126078A (ru) | Антитело против nr10 и его применение | |
| UA117294C2 (uk) | Імунокон'югат | |
| EA201391159A1 (ru) | Hla-рестриктированные пептидоспецифические антигенсвязывающие белки | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2016513664A5 (hr) |